AEs leading to trial product discontinuation occurred in 51/603 (8.5%) participants in the CagriSema 2.4 mg/2.4 mg group, 40/605 (6.6%) participants in the semaglutide 2.4 mg group, 7/152 (4.6%) participants in the cagrilintide 2.4 mg group, 42/594 (7.1%) participants in the CagriSema 1 mg/1 mg group, 26/608 (4.3%) participants in the semaglutide 1 mg group, and 2/149 (1.3%) participants in the placebo group
For peptide researchers running protocols that last weeks or months, these compliance advantages compound
Even mild sleep restriction can increase daily caloric intake by several hundred calories and preferentially shift food cravings toward high-fat, high-sugar options
Christopher Gillis, MD, FRCSC, FAANS Dr
A creamy yellow spot on the underside of the watermelon indicates the fruit is ripe